Clinical trial specialist selects Ventura for Americas HQ
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen gives confidence to investors on pending purchase
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind excites investors, analysts after huge bump in sales
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen delivers earnings beat despite acquisition headaches
Amgen delivered a sound beat of Wall Street analysts’ predictions for its second quarter of 2023 en route to posting a record revenue. The biotech giant reported a total revenue of just under $7 billion, beating the Yahoo Finance estimate by 4.6% and causing the stock to jump up 2.3% in after-hours trading. Amgen attributed Read More →
High expectations: Acelyrin’s founder believes company could become “world’s best”
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.